FiercePharma, by Arlene Weintraub, Jan 29, 2019 When Dave Lennon, president of Novartis unit AveXis, said in November that the company’s experimental gene therapy to treat spinal muscular atrophy (SMA) could be cost-effective at a price of $4 million to $5 million, some pricing critics immediately raised red flags. But then the Institute for Clinical […]
FiercePharma, by Angus Liu, Jan 29, 2019 Pfizer has launched China’s first pay-for-performance program in oncology with its blockbuster breast cancer drug Ibrance, China Daily reported. Under the new program, called Bo’ai Xin’an, Pfizer promises reimbursement of up to 33.5% of Ibrance costs if an enrolled patient’s disease progresses within four months. The U.S. pharma set […]
FiercePharma / by Eric Sagonowsky onMay 3, 2017 On the heels of highly anticipated cardiovascular outcomes data for PCSK9 med Repatha, Amgen has signed a money-back guarantee with Harvard Pilgrim. Through the first-of-its-kind contract, if a patient on Repatha has a heart attack or stroke, the drugmaker will provide a full refund. As the […]
February 25, 2016 | By Tracy Staton in FiercePharma In an article in Science Translational Medicine, researchers from the Massachusetts Institute of Technology, Dana-Farber Cancer Institute and the Broad Institute say patient loans could be designed to link payment to the clinical benefits of their treatment. In a way, they would be pay-for-performance deals–an idea […]